Skip to content

Developing an Adaptive Lifestyle Intervention Program in Family Medicine Clinics

Using the Sequential Multiple Assignment Randomized Trial Experimental Approach to Develop an Adaptive Lifestyle Intervention Program in Family Medicine Clinics

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04392284
Enrollment
40
Registered
2020-05-18
Start date
2021-04-19
Completion date
2022-06-03
Last updated
2025-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance, Obesity, Diabetes, Hypertension, Dyslipidemias, Metabolic Syndrome

Keywords

insulin resistance

Brief summary

The purpose of this study is to investigate the feasibility of conducting a multicomponent lifestyle intervention research study within the UAB Family Medicine Clinic at Highlands and to obtain preliminary data on the effectiveness of the adaptive treatment strategies being investigated to produce improvements in insulin resistance. This study is a Sequential Multiple Assignment Randomized Trial (SMART) with initial randomization groups of individualized nutrition counseling vs. individualized exercise counseling. Note that these initial nutrition or exercise interventions are NOT intended to produce significant weight loss. Participants that do not sufficiently improve their insulin resistance score after 8 weeks will be re-randomized to 2nd stage interventions of either receiving dietary counseling for weight loss or receiving a prescription for metformin. We will collect data on the effectiveness of the intervention to improve insulin resistance/metabolic health in the family medicine clinic as well as potential predictors or moderators of treatment success.

Interventions

BEHAVIORALDiet Counseling

Delivery of nutrition counseling intervention to improve diet quality. Suggested energy intake will be prescribed with the intent to maintain energy balance and current body weight. A total of 16 nutrition counseling sessions lasting \ 30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of nutrition counseling through the end of the study, meeting with the dietitian every other week. Starting at week 9, those identified as non-responding participants will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin.

Delivery of exercise counseling intervention to increase engagement in physical activity. The exercise specialist will counsel participants to progressively increase their weekly physical activity. Weight loss is not a primary goal of these exercise counseling sessions. A total of 16 exercise counseling sessions lasting \ 30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of exercise counseling through the end of the study, meeting with the exercise specialist every other week. Starting at week 9, those identified as non-responders will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin.

Sponsors

University of Alabama at Birmingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Sequential Multiple Assignment Randomized Trial (SMART)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Male or female * Any race or ethnicity * BMI \>27 kg/m2 * Presence of 1 or more mild-to-moderate obesity-associated metabolic complications (i.e., Stage 1 Obesity) * Prediabetes, type 2 diabetes (see

Exclusion criteria

for additional details), metabolic syndrome, dyslipidemia, hypertension, non-alcoholic fatty liver disease * Stable medication type and dosage for ≥3 months

Design outcomes

Primary

MeasureTime frameDescription
Treatment credibilityBaselineAssessment of participants' perception of treatment success using the Credibility/Expectancy Questionnaire with a 9-point Likert scale, ranging from not at all (1) to very (9) for several descriptors (e.g., useful, logical.)
Rates of recruitment and retentionBaselineNumber of participants recruited and retained in intervention
Family medicine clinician referral ratesBaseline
Number of counseling sessions attendedMonth 2Attendance to Zoom meetings
Frequency of metformin adherence (as applicable)Month 2Number of times metformin was taken as prescribed
Intervention preferenceBaselinePreference is determined by the Intervention Preference Questionnaire, using a 5-point Likert Scale for preference among study treatment arms. Scale includes options for strong, slight, or no preference for a given treatment component.

Secondary

MeasureTime frameDescription
Changes in body weightBaseline to Months 2 and 6
Changes in body composition (fat and lean mass)Baseline to Months 2 and 6Fat mass and lean mass via bioelectrical impedance analysis
Changes in glucoseBaseline to Months 2 and 6Serum glucose will be measured in a fasted state
Changes in insulinBaseline to Months 2 and 6Serum insulin will be measured in a fasted state
Changes in glycosylated hemoglobin (hemoglobin A1C)Baseline to Months 2 and 6Percentage (%) glycated hemoglobin as a measure of long-term blood glucose control
Changes in lipidsBaseline to Months 2 and 6Fasting serum concentrations of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026